NASDAQ · RPTX
Healthcare · Biotechnology
$2.65
Up+$0.00 (+0.00%)
Updated Sep 12, 2026, 11:25 PM
SID Score
4.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
RPTX does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning RPTX.
RPTX research
Company profile and research snapshot.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 27, 2025 | HC Wainwright & Co. | Buy | — |
| Mar 7, 2025 | HC Wainwright & Co. | Buy | — |
| Dec 13, 2024 | Stifel | Buy | — |
| Dec 13, 2024 | LifeSci Capital | Market Perform | — |
| Nov 8, 2024 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
globenewswire.com · Dec 8, 2025
BALA CYNWYD, Pa., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning RPTX.
